A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
Conclusions Ontuxizumab, up to a dosage of 12 mg/kg weekly, was generally safe and well tolerated in this population, with no dose-limiting toxicities. The maximum tolerated dose was not reached; 8 mg/kg weekly or 12 mg/kg biweekly were the recommended dosages. We observed long-term disease stabilization in GC and extraskeletal chondrosarco ma, and tumor shrinkage in gastrointestinal stromal tumor and HCC.Trial registration: NCT01773434 (ClinicalTrials.gov).
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Constipation | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Hepatocellular Carcinoma | Investigational New Drugs | Japan Health | Liver Cancer | Study | Toxicology